Tag: Health Care

Displaying 1 - 20 of 909 results.

Pages

Filtering by content type: Advocacy Filing

FTC staff submitted a comment, as public testimony, regarding proposed legislation that would allow licensed Alaska physicians located out-of-state to provide telehealth services in the same manner as in-state physicians. The comment noted that eliminating the in-state requirement...
FTC staff submitted a comment, in response to a request from Kentucky State Representative Tom Burch, on the competitive implications of proposed legislation that would license and regulate denturists within Kentucky. The comment recommended that the legislature consider the...

Filtering by content type: Press Release

Federal Trade Commission staff submitted written comments opposing proposed legislation in Alabama that purports to immunize “authorities” formed by any public university operating a medical school in Alabama, and their collaborative activities “with all types of health care providers,” from the...
The Federal Trade Commission has created a new web-based tool for developers of health-related mobile apps, which is designed to help the developers understand what federal laws and regulations  might apply to their apps. The FTC developed the tool in conjunction with the Department of Health and...
Federal Trade Commission staff submitted a comment, as public testimony, to the Alaska legislature on proposed legislation that would allow licensed Alaska physicians located out-of-state to provide telehealth services in the same manner as in-state physicians. 
Federal Trade Commission staff submitted a comment on the competitive implications of proposed legislation that would license and regulate denturists within Kentucky.  Denturists are trained to make and fit removable partial and full dentures. Currently, Kentuckians who need dentures must obtain...
In testimony before Congress today, the Federal Trade Commission outlined its work to protect consumers in the growing area of health information technology.
The Federal Trade Commission filed an amicus brief with the U.S. Court of Appeals for the Third Circuit urging the court to correct four legal errors in a district court’s antitrust analysis of an alleged reverse-payment agreement involving brand-name pharmaceutical company GlaxoSmithKline and...
Federal Trade Commission staff submitted written comments on the competitive impact of provisions in proposed legislation in West Virginia that would provide for  “cooperative agreements” between health care providers, and provisions purporting to confer “exemptions” from federal antitrust laws on...

Filtering by content type: Public Statement

Filtering by content type: Plain Language Guidance

Start with Security: A Guide for Business offers tips for any business wanting to implement sound data security. For health app developers, here’s tailored advice and additional questions to ask.
What Are the Laws? Which Laws Apply to My Mobile Heath App? Glossary

Filtering by content type: Blog Post

For more than 15 years, one of the FTC’s top priorities has been to put an end to anticompetitive reverse-payment settlements between brand-name drug makers and their potential generic rivals. In our view, these settlements are anticompetitive agreements not to compete in which the...
There is a basic but important difference between antitrust cases brought by the government and those brought by private parties: All plaintiffs, including government enforcers like the FTC, must prove an antitrust violation, which requires showing harm to competition. But private...

Filtering by content type: Amicus Brief

Brief of the Federal Trade Commission arguing that the district court committed multiple legal errors that should be corrected on appeal. The district court erroneously concluded that a reverse-payment settlement that allowed the underlying patent litigation to continue, while the...

Filtering by content type: Case

Drug manufacturer Hikma Pharmaceuticals PLC agreed to sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that its proposed $2 billion acquisition of Roxane would likely be anticompetitive...
Generic drug marketer Hikma Pharmaceuticals PLC agreed to divest its rights and interests in five generic injectable pharmaceuticals to settle charges that its $5 million acquisition of the rights to various drug products and related assets from Ben Venue Laboratories, Inc. would...
Generic drug manufacturers Lupin Ltd. and Gavis Pharmaceuticals LLC agreed to sell the rights and assets for two generic drugs, in order to settle FTC charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive.The merger would have combined two of...

Pages